Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Graviton

Request full access

A bioscience corportation

New York City, United StatesFounded 2020Biotech & Life Sciences

About Graviton

Graviton Bioscience Corp., a clinical-stage biotechnology company headquartered in New York, was established in 2020 by the seasoned biotech entrepreneur Dr. Samuel Waksal. Dr. Waksal's extensive background includes founding ImClone Systems, which was later acquired by Eli Lilly, and Kadmon Pharmaceuticals, acquired by Sanofi. His experience at Kadmon was particularly pivotal as he led the development of the first approved ROCK2 inhibitor, a class of drugs central to Graviton's focus.

The company directs its efforts toward discovering and developing novel therapies for a range of serious conditions, including fibrotic, autoimmune, and central nervous system (CNS) diseases. Graviton's scientific approach centers on inhibiting the Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), a protein implicated in the pathology of numerous disorders that currently have inadequate or no treatment options. The business model is rooted in intensive research and development to create a pipeline of drug candidates. Revenue generation is anticipated through strategic partnerships, licensing agreements, and eventual commercialization of its therapies.

Graviton's lead drug candidate, GV101, is a selective ROCK2 inhibitor currently progressing through clinical trials. This compound has demonstrated an ability to penetrate the blood-brain barrier in preclinical studies and has shown a favorable safety profile in early clinical trials. The company's strategy involves forging collaborations with major pharmaceutical firms to accelerate development and commercialization. Notable partnerships include a strategic investment from Sanofi, which grants them the right of first negotiation to license compounds, and alliances with Ovid Therapeutics and Sino Biopharmaceutical Limited to advance ROCK2 inhibitors for specific indications like Cerebral Cavernous Malformations and other CNS diseases.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Jan 2024 $0 — Sanofi ↗
EARLY VCOther financing Dec 2023 $35M $199M Enavate Sciences ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Graviton website traffic

Latest recorded traffic for Graviton is 710 monthly website visits, down 45.4% over the last three months.

Latest monthly visits710 3-month web change-45.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Graviton in the New York City ecosystem

Live from Dealroom

The Graviton office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Enavate Sciences
  • Sanofi
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Graviton on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Graviton’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.